MA29015B1 - Agents de liaison specifiques de l'angiopoietine-2 - Google Patents

Agents de liaison specifiques de l'angiopoietine-2

Info

Publication number
MA29015B1
MA29015B1 MA29892A MA29892A MA29015B1 MA 29015 B1 MA29015 B1 MA 29015B1 MA 29892 A MA29892 A MA 29892A MA 29892 A MA29892 A MA 29892A MA 29015 B1 MA29015 B1 MA 29015B1
Authority
MA
Morocco
Prior art keywords
angiopoietin
specific binding
binding agents
agents
specific
Prior art date
Application number
MA29892A
Other languages
English (en)
French (fr)
Inventor
Jonathon Daniel Oliner
Kevin Graham
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/982,440 external-priority patent/US7658924B2/en
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of MA29015B1 publication Critical patent/MA29015B1/fr

Links

MA29892A 2004-10-19 2007-05-11 Agents de liaison specifiques de l'angiopoietine-2 MA29015B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US62016104P 2004-10-19 2004-10-19
US10/982,440 US7658924B2 (en) 2001-10-11 2004-11-04 Angiopoietin-2 specific binding agents

Publications (1)

Publication Number Publication Date
MA29015B1 true MA29015B1 (fr) 2007-11-01

Family

ID=39608222

Family Applications (1)

Application Number Title Priority Date Filing Date
MA29892A MA29015B1 (fr) 2004-10-19 2007-05-11 Agents de liaison specifiques de l'angiopoietine-2

Country Status (10)

Country Link
JP (2) JP2008520188A (enExample)
CN (1) CN101495513B (enExample)
BR (1) BRPI0518209A (enExample)
EA (1) EA011866B1 (enExample)
IL (1) IL182279A0 (enExample)
MA (1) MA29015B1 (enExample)
MX (1) MX2007004247A (enExample)
RU (2) RU2404992C2 (enExample)
SG (1) SG156668A1 (enExample)
ZA (1) ZA200704020B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2
JO3182B1 (ar) * 2009-07-29 2018-03-08 Regeneron Pharma مضادات حيوية بشرية عالية الالفة مع تولد الاوعية البشرية - 2
EA022546B1 (ru) * 2011-09-28 2016-01-29 Федеральное Государственное Бюджетное Учреждение Науки Институт Биоорганической Химии Им. Академиков М.М. Шемякина И Ю.А. Овчинникова Российской Академии Наук Способ торможения роста карциномы эрлиха у лабораторного животного
PE20142361A1 (es) * 2011-09-30 2015-01-16 Dana Farber Cancer Inst Inc Peptidos terapeuticos
AU2013212587B2 (en) * 2012-01-23 2017-07-20 Regeneron Pharmaceuticals, Inc. Stabilized formulations containing anti-Ang2 antibodies
US9534007B2 (en) 2012-12-21 2017-01-03 The Regents Of The University Of California Methods and compositions for treatment of cyanide and hydrogen sulfide toxicity
NZ714049A (en) 2013-05-14 2020-05-29 Eisai R&D Man Co Ltd Biomarkers for predicting and assessing responsiveness of endometrial cancer subjects to lenvatinib compounds
AR100270A1 (es) * 2014-05-19 2016-09-21 Lilly Co Eli Anticuerpos ang2
HRP20221047T1 (hr) 2014-08-28 2022-11-11 Eisai R&D Management Co., Ltd. Derivat kinolina visoke čistoće i postupak za njegovu proizvodnju
HUE064614T2 (hu) 2015-02-25 2024-04-28 Eisai R&D Man Co Ltd Eljárás egy kinolin-származék keserû ízének elnyomására
CA2978226C (en) 2015-03-04 2025-02-18 Eisai R&D Management Co., Ltd. COMBINATION OF A PD-1 ANTAGONIST AND A VEGFR/FGFR/RET TYROSINE KINASE INHIBITOR TO TREAT CANCER
BR112017027227B1 (pt) 2015-06-16 2023-12-12 Eisai R&D Management Co., Ltd Agente anti-câncer
MX381976B (es) 2015-08-20 2025-03-13 Eisai R&D Man Co Ltd Agente terapéutico contra tumores.
CN106512006A (zh) * 2016-07-25 2017-03-22 广州道瑞医药科技有限公司 Angpt2分泌抑制剂在制备用于治疗血管瘤的药物中的应用
CN106075448A (zh) * 2016-07-25 2016-11-09 广州道瑞医药科技有限公司 Angpt2抑制剂在制备用于治疗血管瘤的药物中的应用
KR102539920B1 (ko) 2017-02-08 2023-06-05 에자이 알앤드디 매니지먼트 가부시키가이샤 종양-치료용 약제학적 조성물
RU2019134940A (ru) 2017-05-16 2021-06-16 Эйсай Ар Энд Ди Менеджмент Ко., Лтд. Лечение гепатоцеллюлярной карциномы
CN109096368B (zh) * 2018-09-30 2021-07-20 华南理工大学 一种同时具有抗氧化和护肝活性的多肽及编码该多肽的基因与其制备方法和应用
SG11202108832XA (en) * 2019-02-25 2021-09-29 Pharmabcine Inc Anti-ang2 antibody and use thereof
CN112126671B (zh) * 2020-08-18 2021-08-31 中山大学附属第五医院 无乳链球菌Streptococus agalactiae治疗子宫内膜异位症的应用
CN116265487B (zh) * 2021-12-16 2025-01-10 三优生物医药(上海)有限公司 抗ang2-vegf双特异性抗体及其用途

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2199804T3 (es) * 1999-03-26 2004-03-01 Regeneron Pharmaceuticals, Inc. Modulacion de la permeabilidad vascular por medio de activadores del receptor tie2.
CA2372053C (en) * 1999-04-28 2008-09-02 Board Of Regents, The University Of Texas System Compositions and methods for cancer treatment by selectively inhibiting vegf
AU784231B2 (en) * 2000-06-23 2006-02-23 Schering Aktiengesellschaft Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use (II)
US7205275B2 (en) * 2001-10-11 2007-04-17 Amgen Inc. Methods of treatment using specific binding agents of human angiopoietin-2
US7521053B2 (en) * 2001-10-11 2009-04-21 Amgen Inc. Angiopoietin-2 specific binding agents
DK2332523T4 (da) * 2001-10-12 2022-02-21 Aquestive Therapeutics Inc Ensartede film til hurtigtopløsende doseringsform indeholdende smagsmaskerende præparater
BRPI0518209A (pt) * 2004-10-19 2008-11-04 Amgen Inc agentes de ligação especìficos à angiopoietina-2

Also Published As

Publication number Publication date
EA200700876A1 (ru) 2007-10-26
IL182279A0 (en) 2007-07-24
SG156668A1 (en) 2009-11-26
JP2011207882A (ja) 2011-10-20
RU2404992C2 (ru) 2010-11-27
MX2007004247A (es) 2007-06-12
RU2007118670A (ru) 2008-12-27
RU2010132956A (ru) 2012-02-10
JP2008520188A (ja) 2008-06-19
EA011866B1 (ru) 2009-06-30
CN101495513A (zh) 2009-07-29
CN101495513B (zh) 2014-08-06
ZA200704020B (en) 2008-06-25
BRPI0518209A (pt) 2008-11-04

Similar Documents

Publication Publication Date Title
MA29015B1 (fr) Agents de liaison specifiques de l'angiopoietine-2
NO20041907L (no) Angiopoietin-2 spesifikke bindinsmidler
EP1819385A4 (en) NEEDLE ACQUISITION MECHANISMS
SMT202000607T1 (it) Proteine leganti l'interleuchina-13
EP1771786A4 (en) SAMPLE PROCESSING SIMULTANEOUS
EP1896040A4 (en) Phosphoramidate alkylator PRODRUGS
EP1746141A4 (en) THICKENER
EP1827473A4 (en) MODULATOR OF ALPHA SYNNUCLEINE TOXICITY
FR2871145B1 (fr) Distributeur d'applicateurs
DE60134988D1 (de) Verknüpfbare elastomerzusammensetzung
FR2875398B1 (fr) Implant articulaire d'interposition
EP1924684A4 (en) Transition state structure of 5'-methylthioadenosine/s-adenosylhomocysteine nucleosidases
EP1714656A4 (en) ED-71 preparation
EP1741218A4 (en) IMPROVED EXTENSION MOBILITY
MA28812B1 (fr) Combinaisons d'epothilone
IL190045A0 (en) Use of c3-c10 17 alfa-esters of 9,11-dehydrocortexolone as anti-gonadotrophic agents
EP1704857A4 (en) ABCA1 STABILISATOR
FR2880793B1 (fr) Prothese d'epaule
EP1819722A4 (en) MODULATION OF OVULATION
GB2409587B (en) 'Kwicap'
GB0510474D0 (en) Q's vaginometer
EP1756276A4 (en) KRUST ANIMAL EXPRESSION VECTOR
FR2878004B3 (fr) Ferrure d'angle
FR2852042B1 (fr) Piece d'aretier
ITSV20040008A1 (it) Dottor "g"